bronchial asthma crisis predominantly allergic asthma
Conditions
Interventions
58 patients were recruited and divided into two groups: Ciclesonida group (study group) and Hydrocortisone group (control group).
In the study group, 31 patients received 3 ciclesonide (480 mcg) at 5,
Drug
Sponsors
Universidade Federal de São Paulo-Escola Paulista de Medicina
Universidade Federal de São Paulo-Escola Paulista de Medicina
Eligibility
Inclusion criteria
Inclusion criteria: Asthmatic patients aged greater than 13 years, with no upper limit and of both sexes, diagnosed with asthma according to the criteria of the GINA (Global Initiative for Asthma), moderate or severe asthma,that is, with lower FEV1 50 %.
Exclusion criteria
Exclusion criteria: Excluded patients with a body temperature greater than or equal 37,8º; smoking; pregnant women; patients in psychiatric treatment or with a history of heart disease, liver, kidney or other diseases that prevent the use of corticosteroids; patients in the postoperative pulmonary resection in treatment for pulmonary tuberculosis or fungal infection, tracheostomy or mechanical obstruction of the trachea. Patients with myopathy or neurological sequelae (stroke or encephalopathy) that prevent the implementation of the measures necessary for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome: Clinical improvement. To evaluate clinical improvement of patients treated with inhaled Ciclesonide in the asthma crisis. We used the Borg scale from 0 to 10, we considered improvement when the patient, after using the medication, reported that their dyspnea had regressed to a number less than or equal to 2. Physical examination where we evaluated the use of ascessory musculature (sternocleidomastoid) and wheezing the pulmonary auscultation. For this we used a subjective scale of 0 to 3, we considered improvement when there was no more use of ascessory musculature and reduction of wheezing at pulmonary auscultion. ;Outcome: Clinical Improvement We found that inhaled Ciclesonide, in high doses, clinically improves patients with acute asthma compared to endovenous corticosteroid hydrocortisone, when we used the Borg scale for dyspnea, pulmonary auscultation and use of ascessory muscle as parameters.;Outcome: Spirometric and Peak Flow Parameters. We evaluated the study and control group, consecutively,, consecutively, the volume expired in the first second (FEV1) by spirometry and flow measurements by peak flow equipment. We expected that in both parameters there would be elevation to reach 70% of predicted for age, sex, weight, height of the patient.;Outcome: Spirometric and Peak Flow Parameters. We observed that at the end of the study, in both groups the patients reached 70% predicted for their age, gender, weight and height.;Outcome: Spirometric and Peak Flow Parameters. We evaluated the study and control group, consecutively,, consecutively, the volume expired in the first second (FEV1) by spirometry and flow measurements by peak flow equipment. We expected that in both parameters there would be elevation to reach 70% of predicted for age, sex, weight, height of the patient.;Outcome: Spirometric and Peak Flow Parameters. We observed that at the end of the study, in both groups the patients reached 70% predicted for their age, gender, weight and heigh | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome: Evaluate side effects. To evaluate adverse effects such as dry mouth, headache, palpitation, tremors and anxiety in the study and control group.;Outcome: Evaluate side effects. In both groups there was no difference in side effects.;Outcome : Hospitalization rate. Evaluate hospitalization rate after use of inhaled corticosteroid ciclesonide compared with intravenous corticosteroid hydrocortisone in patients with acute asthma crisis;Outcome : Hospitalization rate. There was no difference between the study group and the control group when we evaluated the hospital admission rate. | — |
Countries
Brazil
Contacts
Public ContactDemetrius Martins
Universidade Federal de São Paulo-Escola Paulista de Medicina
Outcome results
None listed